ICU Medical, Inc. (NASDAQ:ICUI) Receives $179.00 Consensus Target Price from Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has been given an average recommendation of “Buy” by the five brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, two have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $179.00.

ICUI has been the subject of a number of research analyst reports. Raymond James Financial cut their price target on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a report on Friday, August 8th. Piper Sandler initiated coverage on shares of ICU Medical in a report on Friday. They issued an “overweight” rating and a $145.00 price target for the company. Wall Street Zen downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Finally, KeyCorp cut their price target on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a report on Monday, April 21st.

Insider Activity

In related news, CEO Vivek Jain acquired 21,929 shares of the business’s stock in a transaction on Thursday, August 14th. The shares were purchased at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the acquisition, the chief executive officer owned 130,149 shares in the company, valued at approximately $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Christian B. Voigtlander sold 4,985 shares of the business’s stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total value of $640,572.50. Following the sale, the chief operating officer owned 6,088 shares in the company, valued at approximately $782,308. The trade was a 45.02% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,889 shares of company stock worth $1,933,186. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of ICU Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Xponance Inc. grew its position in ICU Medical by 5.3% in the first quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier’s stock worth $238,000 after acquiring an additional 86 shares in the last quarter. LPL Financial LLC lifted its stake in shares of ICU Medical by 2.0% in the fourth quarter. LPL Financial LLC now owns 4,816 shares of the medical instruments supplier’s stock worth $747,000 after buying an additional 93 shares during the last quarter. Moody National Bank Trust Division lifted its stake in shares of ICU Medical by 0.9% in the second quarter. Moody National Bank Trust Division now owns 10,751 shares of the medical instruments supplier’s stock worth $1,421,000 after buying an additional 93 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of ICU Medical by 4.5% in the second quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock worth $325,000 after buying an additional 107 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Stock Performance

ICUI stock opened at $120.95 on Friday. The company has a market capitalization of $2.99 billion, a P/E ratio of -79.57 and a beta of 0.88. The company has a 50-day simple moving average of $128.20 and a 200 day simple moving average of $138.02. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $196.26. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, topping the consensus estimate of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The business had revenue of $543.57 million during the quarter, compared to the consensus estimate of $543.33 million. During the same quarter in the prior year, the company posted $1.56 earnings per share. The company’s quarterly revenue was down 8.0% compared to the same quarter last year. Sell-side analysts predict that ICU Medical will post 4.11 earnings per share for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.